Steigerwald Gordon & Koch Inc. Raises Position in Merck & Co., Inc. (NYSE:MRK)

Steigerwald Gordon & Koch Inc. grew its holdings in shares of Merck & Co., Inc. (NYSE:MRKGet Rating) by 19.8% in the 2nd quarter, according to its most recent disclosure with the SEC. The fund owned 4,989 shares of the company’s stock after purchasing an additional 823 shares during the period. Steigerwald Gordon & Koch Inc.’s holdings in Merck & Co., Inc. were worth $455,000 as of its most recent SEC filing.

Several other large investors have also recently made changes to their positions in the business. Joseph P. Lucia & Associates LLC bought a new stake in shares of Merck & Co., Inc. during the first quarter valued at approximately $25,000. Landmark Wealth Management LLC bought a new stake in Merck & Co., Inc. in the 1st quarter worth approximately $25,000. Front Row Advisors LLC grew its position in Merck & Co., Inc. by 89.4% in the 4th quarter. Front Row Advisors LLC now owns 339 shares of the company’s stock worth $26,000 after purchasing an additional 160 shares during the period. Okabena Investment Services Inc. bought a new stake in Merck & Co., Inc. in the 4th quarter worth approximately $27,000. Finally, Western Pacific Wealth Management LP bought a new stake in shares of Merck & Co., Inc. during the 4th quarter valued at $29,000. 73.33% of the stock is currently owned by hedge funds and other institutional investors.

Merck & Co., Inc. Stock Performance

Shares of NYSE:MRK opened at $87.51 on Friday. The company has a market capitalization of $221.69 billion, a price-to-earnings ratio of 13.40, a PEG ratio of 1.14 and a beta of 0.33. Merck & Co., Inc. has a 12 month low of $71.50 and a 12 month high of $95.72. The firm’s 50-day moving average is $88.83 and its 200 day moving average is $87.81. The company has a current ratio of 1.39, a quick ratio of 1.15 and a debt-to-equity ratio of 0.66.

Merck & Co., Inc. (NYSE:MRKGet Rating) last issued its earnings results on Thursday, July 28th. The company reported $1.87 EPS for the quarter, topping analysts’ consensus estimates of $1.67 by $0.20. The business had revenue of $14.59 billion for the quarter, compared to the consensus estimate of $13.85 billion. Merck & Co., Inc. had a net margin of 29.00% and a return on equity of 48.45%. The company’s revenue for the quarter was up 28.0% compared to the same quarter last year. During the same period in the prior year, the firm earned $1.31 EPS. Research analysts predict that Merck & Co., Inc. will post 7.33 EPS for the current year.

Merck & Co., Inc. Dividend Announcement

The business also recently announced a quarterly dividend, which will be paid on Friday, October 7th. Shareholders of record on Thursday, September 15th will be paid a $0.69 dividend. The ex-dividend date is Wednesday, September 14th. This represents a $2.76 dividend on an annualized basis and a yield of 3.15%. Merck & Co., Inc.’s dividend payout ratio is currently 42.27%.

Analyst Ratings Changes

MRK has been the subject of a number of recent research reports. Atlantic Securities boosted their price objective on shares of Merck & Co., Inc. from $105.00 to $110.00 and gave the company an “overweight” rating in a research report on Wednesday, July 13th. Erste Group Bank raised shares of Merck & Co., Inc. from a “hold” rating to a “buy” rating in a research report on Thursday, August 25th. Cowen boosted their price objective on shares of Merck & Co., Inc. from $95.00 to $102.00 and gave the company a “market perform” rating in a research report on Monday, June 27th. Morgan Stanley boosted their price objective on shares of Merck & Co., Inc. from $88.00 to $92.00 and gave the company an “equal weight” rating in a research report on Friday, July 29th. Finally, Mizuho started coverage on shares of Merck & Co., Inc. in a research report on Friday, June 24th. They set a “buy” rating and a $100.00 price objective for the company. Seven investment analysts have rated the stock with a hold rating, eleven have issued a buy rating and two have assigned a strong buy rating to the company. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $98.28.

About Merck & Co., Inc.

(Get Rating)

Merck & Co, Inc operates as a healthcare company worldwide. It operates through two segments, Pharmaceutical and Animal Health. The Pharmaceutical segment offers human health pharmaceutical products in the areas of oncology, hospital acute care, immunology, neuroscience, virology, cardiovascular, and diabetes, as well as vaccine products, such as preventive pediatric, adolescent, and adult vaccines.

Featured Stories

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Co., Inc. (NYSE:MRKGet Rating).

Institutional Ownership by Quarter for Merck & Co., Inc. (NYSE:MRK)

Receive News & Ratings for Merck & Co. Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Merck & Co. Inc. and related companies with MarketBeat.com's FREE daily email newsletter.